Home > Healthcare > Medical Devices > Therapeutic Devices > Xenotransplantation Market

Xenotransplantation Market Size

  • Report ID: GMI6136
  • Published Date: Jul 2023
  • Report Format: PDF

Xenotransplantation Market Size

Xenotransplantation Market size was valued at USD 12.7 billion in 2022 and is estimated to account for USD 29.9 billion by 2032. Xenotransplantation refers to the transplantation of living cells, tissues, or organs from one species to another, with the transplantation of animal (xenogeneic) organs or tissues into humans. It involves the transfer of biological material across species boundaries to replace or repair damaged or dysfunctional organs in recipients. The objective of xenotransplantation is to address the shortage of human organs available for transplantation by utilizing organs or tissues from non-human animal sources.

 

The rising demand for organ transplantation and the potential of xenotransplantation as a solution will create ample evolution opportunities to the business. For instance, as per the Global Observatory On Donation And Transplantation, more than 144,302 organ transplant procedures were performed in the year 2021. Among which kidney transplants registered highest share with 92,532 procedures worldwide. Moreover, high demand for organ transplants coupled with shortage of organ donors leads to long waiting times and high mortality rates.

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Global market for xenotransplantation was valued at USD 12.7 billion in 2022 and is estimated to account for USD 29.9 billion by 2032, backed by the ongoing R&D in genetic engineering, immunosuppressive therapies, and organ preservation technologies.

The transplant diagnostics segment garnered over USD 5.4 billion in 2022 owing to the growing chronic diseases burden worldwide that leads to surge in the number of organ failure cases.

U.S. market accounted for USD 7 billion in 2022 and will witness considerable market growth during 2023-2032, attributed to the growing prevalence of chronic diseases such as end-stage renal disease, heart failure, and liver failure in the region.

Novartis AG, Immerge BioTherapeutics, Inc., United Therapeutics Corporation, Infigen, Inc., eGenesis, Inc., NZeno Limited, Preservation Solutions, Inc., Xeno Transplants Corporation, F. Hoffmann-La Roche Ltd. and OrganOX Limited among others.

Xenotransplantation Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 353
  • Countries covered: 30
  • Pages: 290
 Download Free Sample